Rep. Robert Bresnahan, Jr. Sells Biogen Inc. (NASDAQ:BIIB) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Biogen Inc. NASDAQ: BIIB. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 4/8/2025.
• Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.

Biogen Stock Performance

NASDAQ:BIIB opened at $118.20 on Friday. The company has a market cap of $17.32 billion, a P/E ratio of 10.56, a P/E/G ratio of 1.51 and a beta of 0.12. The firm's 50 day moving average is $128.33 and its two-hundred day moving average is $144.65. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a return on equity of 14.98% and a net margin of 16.87%. The firm had revenue of $2.43 billion during the quarter, compared to analysts' expectations of $2.25 billion. During the same period last year, the business posted $3.67 earnings per share. The company's quarterly revenue was up 6.2% compared to the same quarter last year. Analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

Insider Activity

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now owns 11,318 shares in the company, valued at $1,697,926.36. The trade was a 43.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

BIIB has been the subject of a number of research reports. Hsbc Global Res cut Biogen from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Oppenheimer set a $205.00 price objective on shares of Biogen in a research note on Friday, May 2nd. Canaccord Genuity Group cut their target price on shares of Biogen from $265.00 to $220.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Truist Financial decreased their price target on shares of Biogen from $210.00 to $199.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Finally, HSBC lowered Biogen from a "buy" rating to a "hold" rating and set a $118.00 price objective on the stock. in a research report on Monday, April 28th. Twenty research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $191.30.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Larson Financial Group LLC increased its holdings in shares of Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 141 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Biogen in the fourth quarter worth $25,000. Opal Wealth Advisors LLC bought a new stake in Biogen during the first quarter valued at $26,000. Vision Financial Markets LLC acquired a new stake in shares of Biogen during the first quarter worth $27,000. Finally, Greykasell Wealth Strategies Inc. bought a new position in shares of Biogen in the 1st quarter worth about $27,000. Institutional investors own 87.93% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.